Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

SUBBIAH, VIVEK

One or more keywords matched the following items that are connected to SUBBIAH, VIVEK

Item Type	Name
Concept	Pyrazoles
Academic Article	Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
Academic Article	Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Academic Article	RET Solvent Front Mutations Mediate Acquired?Resistance to Selective RET Inhibition in?RET-Driven Malignancies.
Academic Article	Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Academic Article	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Academic Article	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Academic Article	Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Academic Article	Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
Academic Article	Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
Academic Article	Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
Academic Article	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Academic Article	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Academic Article	Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Academic Article	Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
Academic Article	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.
Academic Article	Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
Academic Article	Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Academic Article	Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Academic Article	Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
Academic Article	Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Academic Article	Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer.

Search Criteria

Pyrazoles